Page 104 - 《中国药房》2023年16期
P. 104

·药师与药学服务·


          1 例玛尔摩分枝杆菌致中枢神经系统感染合并药物性肝损伤的
          药学实践
                        Δ


                                   2 #
                 1*
          赖 舒 ,阮 一 ,何 瑶 (1.重庆市九龙坡区人民医院药剂科,重庆 400050;2.重庆大学附属中心医院
                           2
          药剂科,重庆 400014)
          中图分类号  R969.3;R378.91      文献标志码  A      文章编号  1001-0408(2023)16-2014-04
          DOI  10.6039/j.issn.1001-0408.2023.16.18

          摘   要  目的  介绍1例玛尔摩分枝杆菌致中枢神经系统感染合并药物性肝损伤患者的药物诊疗方案和相关药学监护,为临床药
          师开展药学实践提供借鉴。方法  临床药师参与 1 例玛尔摩分枝杆菌致中枢神经系统感染合并药物性肝损伤患者的治疗过程。
          考虑到患者头痛加剧,皮肤再次出现红斑,临床药师建议停用异烟肼,将治疗方案调整为利福平胶囊+盐酸乙胺丁醇片+硫酸阿米
          卡星注射液+克拉霉素片四联抗感染,并建议送脑脊液样本行二代基因测序以明确病原菌;待确认病原菌为玛尔摩分枝杆菌后,临
          床药师建议维持上述四联方案治疗;当患者出现药物性肝损伤后,临床药师协助医师调整用药方案,以盐酸莫西沙星片替代利福
          平胶囊,予谷胱甘肽片保肝治疗,并行肝肾功能、心电图监测。结果与结论  医师采纳临床药师的建议;患者病情好转,准予出院。
          临床药师通过追踪患者的病史和用药史,查阅指南/共识、研究报道等文献资料,结合患者病情和药物作用特点,分析不良反应发
          生原因,及时调整抗感染药物治疗方案并针对不良反应进行对症处理,从药学角度协助医师完善了临床治疗决策,保证了临床用
          药的有效性、安全性。
          关键词  玛尔摩分枝杆菌;中枢神经系统感染;药物性肝损伤;临床药师;药学实践

          Pharmaceutical  practice  for  one  case  of  central  nervous  system  infection  caused  by  Mycobacterium
          malmoense combined with drug-induced liver injury
          LAI Shu ,RUAN Yi ,HE Yao(1.  Dept.  of  Pharmacy,Jiulongpo  District  People’s  Hospital  of  Chongqing,
                             2
                  1
                                      2
          Chongqing  400050,China;2.  Dept.  of  Pharmacy,the  Affiliated  Central  Hospital  of  Chongqing  University,
          Chongqing 400014,China)
          ABSTRACT    OBJECTIVE To introduce the drug diagnosis, treatment plan and pharmaceutical care of a case of central nervous
          system  infection  caused  by  Mycobacterium  malmoense  combined  with  drug-induced  liver  injury,  and  to  provide  a  reference  for
          clinical  pharmacists  to  carry  out  pharmaceutical  practice.  METHODS  Clinical  pharmacists  participated  in  the  whole  treatment  of  a
          case  of  central  nervous  system  infection  caused  by  M.  malmoense  combined  with  drug-induced  liver  injury.  Considering  the
          patient’s  headache  worsened  and  the  skin  appeared  red  spot  again,  clinical  pharmacists  suggested  stopping  isoniazid  and  adjusted
          the  quadruple  anti-infection  regimen  to  Rifampicin  capsules+Ethambutol  hydrochloride  tablets+Amikacin  sulfate  injection+
          Clarithromycin  tablets,  and  sending  cerebrospinal  fluid  samples  for  the  next-generation  sequencing  to  identify  the  pathogen. After
          the  pathogen  was  identified  as  M.  malmoense,  clinical  pharmacists  recommend  continuing  the  above  quadruple  regimen. When  the
          patient suffered from drug-induced liver injury, clinical pharmacists assisted physicians to adjust the medication plan, and suggested
          that  Rifampicin  capsules  should  be  discontinued,  Moxifloxacin  hydrochloride  tablets  should  be  used  for  anti-infection  treatment,
          Glutathione  tablets  should  be  used  for  liver  protection  treatment,  and  renal  function  and  electrocardiogram  monitoring  should  be
          performed.  RESULTS  &  CONCLUSIONS  The  physicians  adopted  the  advice  of  clinical  pharmacists,  and  the  patient  was
          discharged  after  the  condition  improved.  Clinical  pharmacists  review  the  patient’s  medical  and  medication  history,  consult
          guidelines/consensus, research reports, and other literature materials, analyze the causes of adverse reactions based on the patient’s
          condition and the characteristics of drug action, adjust the medication plan of anti-infective drugs in a timely manner, and provide
          targeted  treatment  for  adverse  reactions.  From  a  pharmaceutical  perspective,  they  assist  physicians  in  improving  clinical  treatment
                                                              decisions  and  ensuring  the  efficacy  and  safety  of  clinical
              Δ 基金项目 重庆市科卫联合医学科研项目(No.2023MSXM090)
             *第一作者 主管药师,硕士。研究方向:临床药学、药理学、医院                   medication.
          药事管理。E-mail:672305465@ qq.com                       KEYWORDS    Mycobacterium  malmoense;  central  nervous
              # 通信作者 副主任药师,硕士。研究方向:临床药学、药理学、医                 system  infection;  drug-induced  liver  injury;  clinical  phama-
          院药事管理。E-mail:27382552@qq.com                        cists; pharmaceutical practice


          · 2014 ·    China Pharmacy  2023 Vol. 34  No. 16                            中国药房  2023年第34卷第16期
   99   100   101   102   103   104   105   106   107   108   109